Sanofi (NASDAQ:SNY) Stock Position Increased by Easterly Investment Partners LLC

Easterly Investment Partners LLC raised its position in shares of Sanofi (NASDAQ:SNY) by 0.8% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 54,856 shares of the company’s stock after buying an additional 446 shares during the quarter. Easterly Investment Partners LLC’s holdings in Sanofi were worth $2,646,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Synergy Asset Management LLC bought a new stake in Sanofi during the fourth quarter worth approximately $25,000. McClarren Financial Advisors Inc. lifted its holdings in shares of Sanofi by 952.6% during the fourth quarter. McClarren Financial Advisors Inc. now owns 600 shares of the company’s stock worth $28,000 after buying an additional 543 shares during the last quarter. Lee Danner & Bass Inc. bought a new position in Sanofi during the fourth quarter worth $31,000. Sunbelt Securities Inc. raised its position in shares of Sanofi by 72.1% during the third quarter. Sunbelt Securities Inc. now owns 747 shares of the company’s stock valued at $43,000 after buying an additional 313 shares during the last quarter. Finally, Sierra Ocean LLC acquired a new position in Sanofi in the 4th quarter valued at approximately $44,000. Institutional investors and hedge funds own 14.04% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on SNY shares. Sanford C. Bernstein upgraded shares of Sanofi to a “strong-buy” rating in a research note on Thursday, January 30th. Deutsche Bank Aktiengesellschaft raised Sanofi from a “sell” rating to a “hold” rating in a research note on Thursday, January 30th. The Goldman Sachs Group assumed coverage on shares of Sanofi in a research report on Friday, March 21st. They issued a “neutral” rating and a $65.00 price objective for the company. Finally, StockNews.com downgraded shares of Sanofi from a “buy” rating to a “hold” rating in a research report on Thursday, December 12th. Three analysts have rated the stock with a hold rating, one has issued a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $62.50.

Sanofi Stock Performance

NASDAQ:SNY opened at $54.50 on Thursday. The stock has a 50 day simple moving average of $54.94 and a 200 day simple moving average of $52.83. The stock has a market cap of $138.31 billion, a P/E ratio of 21.89, a PEG ratio of 1.01 and a beta of 0.58. Sanofi has a 1-year low of $45.22 and a 1-year high of $60.12. The company has a current ratio of 1.46, a quick ratio of 1.14 and a debt-to-equity ratio of 0.15.

Sanofi (NASDAQ:SNY) last posted its earnings results on Thursday, January 30th. The company reported $0.70 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.70. Sanofi had a return on equity of 25.61% and a net margin of 12.77%. Research analysts anticipate that Sanofi will post 4.36 earnings per share for the current year.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.